ERRATA

Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial

MI Resnick and CG Roehrborn

Prostate Cancer and Prostatic Diseases (2008) **11**, 209; doi:10.1038/sj.pcan.4500981

Correction to: *Prostate Cancer and Prostatic Diseases* (2007) **10**, 155–159; doi:10.1038/sj.pcan.4500925

Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.

For the above article, the co-author CG Roehrborn's affiliation should read as follows:

Androgen decreases osteoprotegerin expression in prostate cancer cells

Prostate Cancer and Prostatic Diseases (2008) **11**, 209; doi:10.1038/sj.pcan.4500993

Correction to: *Prostate Cancer and Prostatic Diseases* (2007) **10**, 160–166. doi:10.1038/sj.pcan.4500927

For the above referenced article, there was a misalignment of entries in Table 1. The correct version of the table is as follows:

Table 1 Basal expression of OPG in human CaP cell lines

Cell line	Total OPG (pg/ml) ^a	Corrected OPG (pg/μg total protein/ml) ^b
LAPC-4	<31.25 ^c	<1.0 ^c
DuCaP	<31.25 ^c	<1.0 ^c
LNCaP-FGC	309.0 ± 10.9	0.0804 ± 0.003
PC-3	55,902.0 ± 11,289.05	15.09 ± 2.98
PZ-HPV-7	49.6 ± 3.05	0.485 ± 0.03

Abbreviation: OPG, osteoprotegerin.

^aOPG levels from media conditioned for 4 days, expressed as mean ± s.d. of four independent experiments.

^bOPG levels corrected for total protein levels.

^cOPG levels produced by LAPC-4 and DuCaP cells were below the detection limits of the ELISA used (31.25 pg/ml).